Revenue
2020
2021
2022
2023
Gain Therapeutics, Inc. (GANX)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | $55,180 | $132,640 | $133,928 | $28,881 |
| Research & development | $10.2M | $10.8M | $11.5M | $8.4M | $7.2M | $2.3M |
| Operating expenses | $18.7M | $20.4M | $22.3M | $17.9M | $14.0M | $3.5M |
| Operating income | −$18.7M | −$20.4M | −$22.3M | −$17.8M | −$13.8M | −$3.5M |
| EBITDAderived | −$18.6M | −$20.3M | −$22.2M | −$17.7M | −$13.8M | −$3.5M |
| Net income | −$20.2M | −$20.4M | −$22.3M | −$17.6M | −$13.9M | −$3.6M |
| Basic EPSper diluted share | -$0.61 | -$0.89 | -$1.71 | -$1.48 | -$1.37 | -$1.33 |
| Diluted EPSper diluted share | -$0.61 | -$0.89 | -$1.71 | -$1.48 | -$1.37 | -$1.33 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Aug 9, 2024Form 4 | Mack GeneCFO and Interim CEO | BuyCommon Stock | 14.4K | $1.01 | $14.5K | 14.4K |
| Aug 9, 2024Form 4 | Islam KhalidExecutive Chairman | BuyCommon Stock | 50.0K | $1.00 | $50.0K | 50.0K |
| Jul 1, 2024Form 4 | RICHMAN ERIC IDirector | BuyCommon Stock | 12.0K | $1.21 | $14.5K | 289.6K |
| Jul 1, 2024Form 4 | RICHMAN ERIC IDirector | BuyCommon Stock | 5.0K | $1.23 | $6.2K | 277.6K |